Gossamer Bio CEO Faheem Hasnain at Endpoints' #BIO22 panel (J.T. MacMillan Photography for Endpoints News)

Gos­samer’s Fa­heem Has­nain de­fends a round of pos­i­tive PAH da­ta as a clear win. But can these PhII re­sults stand up to scruti­ny?

Gos­samer Bio $GOSS post­ed a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment for its pri­ma­ry end­point in the key Phase II TOR­REY tri­al for lead drug ser­a­lu­tinib on Tues­day morn­ing. But CEO Fa­heem Has­nain has some ex­plain­ing to do on the im­por­tant sec­ondary of the cru­cial six-minute walk dis­tance test — which will be the pri­ma­ry end­point in Phase III — as the da­ta on both end­points fell short of ex­pec­ta­tions, miss­ing one an­a­lyst’s bar on even mod­est suc­cess.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.